Friday 23 September
Please find below the programme schedule for Friday 23 September 2022.
Meet the experts session 2
08:00
Suite No. 292 (Ruby) | M2.1 Point of care test
Cornelia Lass Flörl, Austria and Martin Hönigl, Austria
08:00
Suite No. 293 (Sapphire) | M2.2 Allergic fungal lung diseases
Ritesh Agarwal, India and Koichiro Asano, Japan
09:00
Conference hall B | Key note (P6) New azoles in management of invasive mould infections
Johan Maertens, Belgium
Parallel session 7
Parallel session 7 will take place from 10:30 AM - 12:00 PM and consists of five symposia.
Conference hall B | S7.1 Update in management of fungal infection in adult haematology
Chairs: Xiao-Jun Huang, China and Subhash Varma, India
10:30
S7.1a TBD
10:50
S7.1b Breakthrough fungal infection
Dinesh Bhurani, India
11:10
S7.1c New treatment options for management of fungal infections
Johan Maertens, Belgium
11:30
S7.1d* Reliability of bedside point-of-care tests for C. neoformans, M. tuberculosis and S. pneumoniae in adults living with HIV presenting with suspected central nervous system infection (CNS) in low- and middle-income settings: Preliminary results from the DREAMM study
Aude Sturny Leclere, France
11:45
Q&A with all speakers
Conference hall A | S7.2 More than just candidemia: Clinical aspects, diagnosis and treatment, and pathogenesis of deep- seated candidiasis
Chair: Malini Capoor, India
10:30
S7.2a Non- bloodstream deep-seated candidiasis: Clinical spectrum of disease, epidemiology and antifungal resistance
M. Hong Nguyen, USA
10:50
S7.2b Advances in the diagnosis, treatment and prevention of deep-seated candidiasis
Ram Gopalakrishnan, India
11:10
S7.2c Candida- host interactions and pathogenesis of deep-seated candidiasis, and lessons for patient management
Neil Clancy, USA
11:30
S7.2d TBD
11:45
Q&A with all speakers
Suite No. 292 (Ruby) | S7.3 Emergent theories on pathogenic fungal dispersal around the globe
Chairs: Jianping Xu, Canada and Anuradha Chowdhary, India
10:30
S7.3a Emergence and dispersal of Coccidioides in the Western Hemisphere
David Engelthaler, USA
10:50
S7.3b Niche and dispersal of Candida auris
Wieland Meyer, Australia
11:10
S7.3c Evolution of Pseudogymnoascus destructans, the cause of white nose syndrome in bats
Jianping Xu, Canada
11:30
S7.3d* Nuclear Magnetic Resonance based identification of metabolites in Dermatophytes
Vikramjeet Singh, India
11:45
Q&A with all speakers
Suite No. 293 (Sapphire) | S7.4 Pathgenesis and host defense
Chairs: Shibuya Kazutoshi, Japan and Shigeru Kohno, Japan
10:30
S7.4a Vaccine-inducing lung resident CD4+ memory T cells are protective against Cryptococcus gattii infections
Keigo Ueno, Japan
10:50
S7.4b Microaerobic conditions enhance fungal pathogenesis in Candida spp.
Yoshitsugu Miyazaki, Japan
11:10
S7.4c The hidden pathophysiology behind the images of invasive fungal infections
Kazutoshi Shibuya, Japan
11:30
S7.4d* Candida albicans SR-like protein kinases regulate different cellular processes: Sky1 is involved in control of ion homeostasis, while Sky2 is important for dipeptide utilization
Philipp Brandt, Germany
11:45
Q&A with all speakers
Suite No. 294 (Emerald) |S7.5 MMCR case report session
Chairs: Adilia Warris, UK and Rajeev Soman, India
10:30
1. Human protothecosis: a case report in Northeastern Brazil
Conceicao Pedrozo, Brazil
10:40
2. Basidiobolus meristosporus - A new species on the block!
Ruchita Chabra, India
10:50
3. A Psittacine bite and subcutaneous Zygomycosis in immune competent: Case with therapeutic challenge
Shivani Choubey, India
11:00
4. An unusual recurrent case of Cryptococcal sacroilitis in an immunocompetent elderly female in Rajasthan, India
Sidhya Choudhary, India.
11:10
5. Paratracheal abscess by plant fungus Chondrostereum purpureum. First case report of human infection
Soma Dutta, India
11:20
6. Parinaud’s Oculoglandular Syndrome as an atypical manifestation of sporotrichosis in Brazil
Filipe Batista, Brazil
11:30
7. Lodderomyces elongisporus fungemia in a late post-operative patient with ventricular septal defect: case report
Sudesh Gourav, India
11:40
8. First case of cutaneous mycosis caused by Nannizziopsis sp. in Chelonia
Giorgia Matteucci, Italy
11:50
Q&A with all speakers
12:00
Lunch and poster session 3
Conference Hall C - Exhibition
Conference hall B | Sponsored symposium 3: Pipeline session
Chairs: Rajeev Soman, India / Alessandro C. Pasqualotto, Brazil
12:30
Olorofim – first of a novel class of antifungals
Johan Maertens, Belgium
12:45
Opelconazole (PC945): A Novel Inhaled Azole in Late-Stage Clinical Development for Invasive Pulmonary Aspergillosis
Dr. Lance Berman, MB.ChB; M.S. (Pharm. Med.) Chief Medical Officer, Pulmocide Ltd
Invasive aspergillosis (IA) occurs in 4% of patients undergoing remission induction chemotherapy for hematological malignancies, in 9% of allogeneic hematological stem cell transplant recipients [Van de Peppel 2018] and in 2-8% of lung transplant recipients [Samanta 2020, Baker 2020, Ullmann 2018], despite the use of antifungal prophylaxis in these patient groups. Aspergillus is a particularly important opportunistic infection in lung transplant recipients [Pasupneti 2017, Husain 2019] with invasive disease occurring in 2-8% of patients in the first-year post-transplant [Samanta 2020, Baker 2020, Ullmann 2018].
Currently available antifungal therapies have treatment-limiting side effects including drug-drug interactions [Ullmann 2018, Husain 2016]. These pose a significant challenge in patients with an underlying malignancy or in recipients of a solid organ transplant. In lung transplant recipients the anastomotic site is particularly vulnerable due to disruption of blood supply and the presence of sutures [Cho, 2015]. Even with systemic antifungals, mortality rates remain high [Herbrecht, 2019].
There are therefore limited therapeutic options for patients with invasive pulmonary aspergillus disease particularly for those who do not respond to initial therapy or in whom antifungals that are approved for the treatment of invasive aspergillosis are contraindicated.
A potent, effective inhaled anti-fungal agent with prolonged lung tissue residence and minimal systemic update would be a valuable adjunct to current therapeutic options. To date, treatment using inhaled antifungal agents has been limited to repurposing available systemic medicines. PC945 (opelconazole) Nebulizer Suspension is a novel triazole antifungal agent which was specifically designed for inhaled use and which is being developed as an inhaled treatment for pulmonary fungal disease. The profile of opelconazole has been assessed in a range of in vitro and in vivo studies demonstrating that it has potent antifungal activity against A. fumigatus, C. albicans and a range of other fungi [Colley T et al., 2017; Colley et al., 2019]. Following inhaled delivery, local concentrations of opelconazole in the lung are high, while systemic bioavailability is minimal [Cass et al., 2020]. This profile could allow opelconazole to provide effective antifungal activity in the respiratory tract while limiting the potential for systemic side effects.
Opelconazole has been supplied to patients with serious or life-threatening pulmonary aspergillosis who have not responded to available mold-active therapies under a Special Needs program regulated in the United Kingdom by the Medicines and Healthcare products Regulatory Agency. Successful outcomes in the first two patients who developed invasive pulmonary aspergillosis due to infections with A. fumigatus complex shortly after lung transplantation have been reported [Pagani 2020]. Available data from the program, in this non-clinical trial setting, indicate that opelconazole was generally well tolerated with no drug-drug interactions reported in the 11 patients who received opelconazole as treatment and in the 12th patient who received it as prophylaxis. Favorable responses at 3 months were observed in 9 out of the 11 patients who received opelconazole as treatment.
13:00
Ibrexafungerp: First in a New Class Triterpenoid Antifungal in Development for Treatment of Invasive Fungal Infections and Vulvovaginal Candidiasis
Nkechi Azie, MD, MBA, FIDSA, Vice President, Head Clinical Development and Medical Affairs, Scynexis
13:15
Q&A with all speakers
14:00
Conference hall B | Key note (P7): Banging our head against the (fungal) wall
Neil Gow, UK
Parallel sessions 8
Parallel session 8 will take place from 03:00 - 05:30 PM and consists of five symposia.
Conference hall B | S8.1 Tackling Candida auris in resource-limited settings
Chairs: Nelesh Govender, South-Africa and Methee Chayakulkeeree, Thailand
15:00
S8.1a Something along the lines of “A global update on Candida auris’
Tom Chiller, USA
15:20
S8.1b Emergence and establishment of C. auris in Indian hospitals
Anuradha Chowdhary, India
15:40
S8.1c Is a search and destroy strategy still feasible for Candida auris in South Africa?
Nelesh Govender, South-Africa
16:00
S8.1d* Innovative approaches to tackle C. auris in Latin America
Arnaldo Lopes Colombo, Brazil
16:15
Q&A with all speakers
Conference hall A | S8.2 What is new in pediatric mycology?
Chairs: Emmanuel Roilides, Greece and Tanu Singhal, India
15:00
S8.2a Trends in epidemiology of pediatric Candida infections worldwide
Emmanuel Roilides, Greece
15:20
S8.2b Aspergillus spp. in primary immunodeficiencies and cystic fibrosis
Adilia Warris, UK
15:40
S8.2c Updated guidelines in the management invasive fungal infections in paediatrics
Andreas Groll, Germany
16:00
S8.2d* Fungal beta-glucans and mannan performances in HIV-associated histoplasmosis
Antoine Adenis, France
16:15
Q&A with all speakers
Suite No. 292 (Ruby) | S8.3 How the Fungal Cell Wall Glycan Can Modulate the Immune Response?
Chairs: Boualem Sendid, France and Rajendra Prasad, India
15:00
S8.3a Structural aspects
Thierry Fontaine, France
15:20
S8.3b How Fungal Cell Wall Glycans Modulate the Activation of Platelets?
Samir Jawhara, France
15:40
S8.3c Cell wall glycans as targets for the development of new antifungals
Vishukumar Aimanianda, France
16:00
S8.3d* Characterization of glycosylphosphatidylinositol-linked aspartyl proteases in Candida glabrata: role in pathogenicity
Rupinder Kaur, India
16:15
Q&A with all speakers
Suite No. 293 (Sapphire) | S8.4 Veterinary Mycology and One Health Working Group Business Meeting
Chairs : Jacques Guillot, France and Amir Seyedmousavi, USA
S8.5 Genotyping of Cryptococcus neoformans and C. gattii
Chairs: Wieland Meyer, Australia and Carolina Firacative, Colombia
15:00
S8.5a The global MLST database and it use in characterising the population structure of the Cryptococcus neoformans and C. gattii species complexes
Wieland Meyer, Australia
15:20
S8.5b Molecular Epidemiology of the C. neoformans and C. gattii species complexes in India
Ferry Hagen, Netherlands
15:40
S8.5c MLST Genotyping and phylogenetics of AD-hybrids
Massimo Cogliati, Italy
16:00
S8.5d* Cryptococcus neoformans and Cryptococcus gattii clinical isolates from Colombia develop heteroresistance to fluconazole at high concentrations
Carolina Firacative, Colombia
16:15
Q&A with all speakers
16:30
Break
Conference hall C - Exhibition
Parallel session 9
Parallel session 9 will take place from 04:45 - 06:15 PM and consists of five symposia.
Conference hall B | S9.1 Chronic Pulmonary Aspergillosis - where do we stand?
Chair: Inder Paul Singh, India
16:45
S9.1a Diagnostic performance of serological assays to detect Aspergillus-specific antibodies in chronic pulmonary aspergillosis
Malcolm Ricardson, UK
17:05
S9.1b TBD
17:25
S9.1c Current treatment options for CPA and future directions
David Denning, UK
17:45
S9.1d* Chronic pulmonary aspergillosis in post-tb and retreatment tb patients in Lagos, Nigeria
Adeyinka Davies, Nigeria
18:00
Q&A with all speakers
Conference hall A | S9.2 Azole resistance in Aspergillus fumiagatus: how hot is your hotspot?
Chairs: Jacques Meis, Netherlands / Katrien Lagrou, Belgium
16:45
S9.2a Hotspots of AMR in A. fumigatus; sex, drugs & (re) evolution
Harsimran Kaur, India
17:05
S9.2b Hot and Cold: the expanding distribution of triazole-resistance in Aspergillus fumigatus
Jianping Xu, Canada
17:25
S9.2c The potential role of the environment in azole-resistant veterinary A. fumigatus isolates – Penguin in the coalmine?”
Hanne Debergh, Belgium
17:45
S9.2d* Directed evolution of voriconazole resistance in Aspergillus fumigatus identifies novel mutations responsible for triazole resistance
Nir Osherov, Israel
18:00
Q&A with all speakers
Suite No. 292 (Ruby) | S9.3 Drug resistance in emerging pathogenic fungi
Chairs: Rajendra Prasad, India and Kaustuv Sanyal, India
16:45
S9.3a Antifungal resistance in emerging Candida auris
Jeffrey Rybak, Germany
17:05
S9.3b Fighting drug resistance with immunotherapies: Update on the Candida vaccine project
Ashraf Ibrahim, USA
17:25
S9.3c Antifungal drug resistance in clinical isolates of Candida spp: behind the curtains
Dominique Sanglard, France
17:45
S9.3d* Antivirulence drug discovery to disarm Candida albicans with metabolites from myxobacteria
Raghav Vij, Germany
18:00
Q&A with all speakers
Suite No. 293 (Sapphire) | S9.4 Free oral paper session
Chairs: Vijaylata Rastogi, India and Kaustav Sanyal, India
16:45
S9.4a* Ocular infections by melanized fungi Curvularia lunata and Lasiodiplodia theobromae: antifungal susceptibility and clinical outcome
Sanchita Mitra, India
17:05
S9.4b* Trimetallic Cu-Zn-Fe nanoparticles induced apoptosis and cell cycle arrest in multidrug-resistant Candida auris
Hamad Alam, South Africa
17:25
S9.4c* TBD
17:45
S9.4d* Aspergillus fumigatus complicates one third of the patients with suspected bronchial asthma or pulmonary tuberculosis: clinical validation of indigenously developed diagnostic kits
Taruna Madan, India
18:00
Q&A with all speakers
Suite No. 294 (Emerald) | S9.5 Malassezia: pathogenesis and disease
Chair: Shivaprakash Rudramurthy / Bansidhar Tarai, India
16:45
S9.5a Role of Malassezia in Crohns disease and IBD
Shivaprakash Rudramurthy, India
17:05
S9.5b The need for longitudinal testing in human disease
Jayanthi Savio, India
17:25
S9.5c Malassezia/Host interactions and the Il-17/23 axis
Salomé LeibundGut- Landmann, Switzerland
17:45
S9.5d* Genotyping of Malassezia species from seborrheic dermatitis/dandruff patients
Prasanna Honnavar, Antigua & Barbuda
18:00
Q&A with all speakers
19:30
Congress dinner
Sunday Nursery (buses will depart from the entrance of the Ashok at 07:00 PM)